A Phase 1 Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-BVD-523 Following Single Oral Dose Administration in Healthy Male Subjects

Trial Profile

A Phase 1 Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-BVD-523 Following Single Oral Dose Administration in Healthy Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Jul 2017

At a glance

  • Drugs Ulixertinib (Primary)
  • Indications Acute myeloid leukaemia; Cancer; Myelodysplastic syndromes; Pancreatic cancer
  • Focus Pharmacokinetics
  • Sponsors BioMed Valley Discoveries
  • Most Recent Events

    • 11 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 03 Feb 2017 Status changed from not yet recruiting to active, no longer recruiting.
    • 19 Dec 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top